Edition:
United States

Profile: Circassia Pharmaceuticals PLC (CIRCI.L)

CIRCI.L on London Stock Exchange

18.65GBp
23 Aug 2019
Change (% chg)

0.05 (+0.27%)
Prev Close
18.60
Open
18.60
Day's High
18.65
Day's Low
18.50
Volume
243,566
Avg. Vol
3,360,926
52-wk High
82.70
52-wk Low
13.25

Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. Its next-generation immunotherapy is in Phase III testing for cat allergy. Its lead asthma treatment targets substitution of GlaxoSmithKline's (GSK's) Flixotide pMDI. It is developing therapies targeting direct substitution of Seretide pMDI and Serevent pMDI. The Company is also developing a range treatment, including a fixed dose triple combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

Company Address

Circassia Pharmaceuticals PLC

Northbrook House, Robert Robinso
OXFORD     OX4 4GA
P: +441865.405560
F: +441865.784576

Company Web Links